AML-bearing mice were treated with gilteritinib, FLT3scFv/NKG2D-CAR T cells, or the combination of gilteritinib and FLT3scFv/NKG2D-CAR T cells for 3 weeks (Fig. 3A). This evidence concerns the gene KLRK1 and acute myeloid leukemia.